Kyowa Kirin's Q3 2025 revenue dips amid restructuring, R&D spend

Kyowa Kirin's nine-month revenue decreased by 13.3 bn yen (3.7%) to 349.5 bn yen in Q3 2025, with core operating profit down by 12.4 bn yen (16.7%) to 62.0 bn yen. This decline was primarily due to business restructuring in the APAC region, reductions in drug price standards, and higher research and development expenses totaling 76.8 bn yen. However, global strategic products, particularly in North America and EMEA, showed growth.

Profit attributable to owners of parent fell by 23.3 bn yen (41.7%) to 32.6 bn yen, partly due to a gain on sale of investments in subsidiaries in China recorded in the prior year. Despite these challenges, the company's financial position remained stable with total assets increasing by 10.1 bn yen to 1,077.4 bn yen. Dividends remain unchanged from the previous forecast, with an expected annual payout of 60.00 yen.

The company is actively advancing its R&D pipeline, with Rocatinlimab in Phase III trials for atopic dermatitis, ziftomenib undergoing regulatory submission for Acute Myeloid Leukemia, and OTL-200 granted orphan regenerative medicine product designation in Japan. These initiatives underscore Kyowa Kirin's focus on creating life-changing value and global strategic partnerships.